Literature DB >> 25696443

Hypertrophic cardiomyopathy in daily practice: an introduction on diagnosis, prognosis and treatment.

C van der Lee, M J Kofflard, M L Geleijnse, F J Ten Cate.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a complex, inherited cardiac disease that has been subject to intense investigation since it was first described in 1957. Over the past 40 years, understanding has evolved regarding the diagnosis, prognosis and treatment of HCM. Analyses of HCM populations from nonreferral centres have refined the insights into the natural history and the occurrence of sudden cardiac death, which is the most devastating component of its natural history. Therapeutic strategies are diverse and may vary during the course of the disease. Optimal therapy depends on symptoms, haemodynamic findings and the presence of risk factors for sudden cardiac death. At present, invasive therapy for patients with obstructive HCM and drug-refractory symptoms includes surgery or percutaneous transluminal septal myocardial ablation. This report summarises the diagnostic criteria, clinical course and therapeutic management of HCM. Attention is also paid to certain issues of special interest in this disease.

Entities:  

Keywords:  cardiiomyopathy; myectomy; septal ablation

Year:  2005        PMID: 25696443      PMCID: PMC2497370     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  33 in total

Review 1.  Recent advances in the molecular genetics of hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

2.  Prognosis and mortality of hypertrophic obstructive cardiomyopathy.

Authors:  T Hardarson; C S De la Calzada; R Curiel; J F Goodwin
Journal:  Lancet       Date:  1973-12-29       Impact factor: 79.321

3.  Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy.

Authors:  D A Swan; B Bell; C M Oakley; J Goodwin
Journal:  Br Heart J       Date:  1971-09

Review 4.  Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.

Authors:  A J Marian; L Salek; S Lutucuta
Journal:  Minerva Med       Date:  2001-12       Impact factor: 4.806

5.  Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; T J Anan; W C Roberts
Journal:  Circulation       Date:  1981-04       Impact factor: 29.690

6.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle.

Authors:  K Poetter; H Jiang; S Hassanzadeh; S R Master; A Chang; M C Dalakas; I Rayment; J R Sellers; L Fananapazir; N D Epstein
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

7.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

Review 8.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

9.  Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (TPM1) gene in familial hypertrophic cardiomyopathy.

Authors:  Roselie J Jongbloed; Carlo L Marcelis; Pieter A Doevendans; Judith M Schmeitz-Mulkens; Willem G Van Dockum; Joep P Geraedts; Hubert J Smeets
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

10.  Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; E Ciró; P Spirito
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

View more
  1 in total

1.  Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience.

Authors:  M Michels; Y M Hoedemaekers; M J Kofflard; I Frohn-Mulder; D Dooijes; D Majoor-Krakauer; F J Ten Cate
Journal:  Neth Heart J       Date:  2007-05       Impact factor: 2.380

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.